Next generation DNA sequencing could set the stage for a new era in medicine given its accuracy, cost-effectiveness, and soon—affordability.
In the upcoming webcast, Next Generation DNA Sequencing: An Investor Field Guide, Simon Barnett, Analyst, Genomic Revolution, ARK Invest; and Tom Staudt, Chief Operating Officer, ARK Invest, will highlight developments in sequencing, its impact on healthcare, and how financial advisors can gain exposure to next generation DNA sequencing through a diversified investment approach.
As a way to tap into the potential growth of the genomic revolution, ETF investors may look to the ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG). ARKG provides exposure to CRISPR, Targeted Therapeutics, Bioinformatics, Molecular Diagnostics, Stem Cells and Agricultural Biology, according to ARK Invest.
“Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business,” according to ARK Investg.
The fund tracks equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
The active management team behind the ARKG strategy combines a top-down and bottom-up research methodology to identify innovative companies and convergence across markets.
The fund tries to help investors take on a thematic multi-capitalization exposure to innovative elements that cover advancements in gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations. These advancements can also translate over to growth potential, potentially providing investors with long-term alpha with low correlation relative to traditional growth strategies.
Top holdings include Illumina Inc. 9.9%, CRISPR Therapeutics 9.1%, Invitae 8.2, Intellia Therapeutics 6.1%, Editas Medicine 4.9%, Teladoc Health 4.8%, Iovance Biotherapeutics 4.2%, Compugen 4.0%, Cellectis 3.6% and Veracyte 3.3%.
Financial advisors who are interested in learning more about next generation biotech innovations can register for the Thursday, November 14 webcast here.